CSL snags a pre­clin­i­cal stem cell ther­a­py in $416M Cal­im­mune buy­out, plans to spin out HIV ef­fort

CSL Behring has bagged the stem cell gene ther­a­py play­er Cal­im­mune for $91 mil­lion and an­oth­er $325 mil­lion in mile­stones for the years-long clin­i­cal jour­ney …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER